Paul Richards
Hematology & Oncology · Salem, VANPI 1053387266
Payments from drug & device makers
Across 653 payments — averaging $2622.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$904K
- Eli Lilly$343K
- Pfizer$129K
- Novartis$104K
- Eisai Inc.$89K
- Sanofi US Services Inc.$57K
- plus $87K from 23 others
Across 4 payments — averaging $2036.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8K
What the payments were for
- Food & beverage$1,06286%
- Education$17014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 274 | $903,736 |
| Eli Lilly | 31 | $342,697 |
| Pfizer | 143 | $128,711 |
| Novartis | 6 | $103,692 |
| Eisai Inc. | 80 | $89,478 |
| Sanofi US Services Inc. | 25 | $56,967 |
| Tesaro, Inc. | 1 | $34,671 |
| Gilead | 24 | $32,739 |
| Genentech, Inc. | 14 | $10,321 |
| AstraZeneca | 2 | $7,352 |
| Merck | 28 | $912 |
| Amgen | 2 | $185 |
| Immunomedics, Inc. | 1 | $123 |
| Jazz Pharmaceuticals Inc. | 2 | $120 |
| Regeneron Healthcare Solutions, Inc. | 2 | $119 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $118 |
| GE HealthCare | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Tactile Systems Technology Inc | 3 | $90 |
| Lilly USA, LLC | 1 | $84 |
| Johnson & Johnson | 1 | $65 |
| Adaptive Biotechnologies Corporation | 2 | $46 |
| Bristol Myers Squibb | 2 | $37 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,712,562 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 17 | $436 |
| Famotidine | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Salem
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
- Lakshminarayanan NandagopalFredericksburg$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.